Cyprus Japan Forum | Efevre Tech Ltd

1st Business Cyprus-Japan Forum

Bridging Continents with Scientific Innovation:

EFEVRE TECH Presents VITALE at the Cyprus–Japan 2024 Forum

In 2024, the 1st Business Cyprus–Japan Forum brought together visionary leaders, scientists, and investors from two innovation-driven nations; Cyprus and Japan. Set against the backdrop of cross-continental collaboration, the forum focused on exploring opportunities in biotechnology, robotics, and artificial intelligence, positioning Cyprus as a strategic European tech hub. For EFEVRE TECH, this forum was more than a networking opportunity, it was a decisive step toward globalizing its solutions and introducing its pioneering software platform, VITALE, to a new and influential scientific audience.

Introducing VITALE: A Digital Ally Against the Reproducibility Crisis

As part of the conference’s science and innovation track, Dr. Nikolaos Pisimisis was representing EFEVRE TECH when taking the stage to highlight one of modern science’s most pressing concerns: the reproducibility crisis. Dr. Pisimissi highlighted the widespread issue in Life-Science research where a large number of published studies cannot be successfully repeated, a phenomenon widely known as the reproducibility crisis. This challenge significantly undermines clinical progress, leads to inefficient use of resources, and threatens the overall credibility of scientific research.

To address this, Dr. Pisimisis presented a combined solution: the AMGEL robotic device and its intelligent control center, the VITALE software platform. While AMGEL automates and standardizes experimental execution, VITALE acts as the brain of the operation, offering intelligent workflow management, traceability, and predictive insights that support reproducibility at every stage of research.

VITALE was introduced as a modular, AI-powered ecosystem with six core features:

Status/Dashboard: Real-time experiment tracking and system monitoring.
Protocol Designer: A visual tool for creating custom, standardized experimental workflows.
Protocol Library: A curated and validated archive of published protocol procedures.
Scheduling Calendar: Automated laboratory protocol planning with real-time collaboration.
Personal Labbook: A secure, digital, and automated data logging with full traceability.
AI Insights: Predictive analytics and anomaly detection to optimize experimental outcomes.

Dr. Pisimisis emphasized VITALE’s 24/7 usability, noting how researchers can rely on the platform’s efficiency and consistency, especially when conducting critical experiments in reproductive medicine, pharmacology, and diagnostics.

Strategic Value That Gained Towards VITALE’s Development

During the forum, two high-level meetings were arranged with prominent Japanese OEM providers: Nichiryo (nichiryo.co.jp) and Cyfuse Biomedical (cyfusebio.com). Discussions centered around potential collaborations to secure high-quality manufacturing equipment and reliable supply chains critical for the next phase of VITALE's development. Both companies are internationally recognized for their precision engineering and dependable logistics, making them ideal partners to support AMGEL's manufacturing, VITALE's development and global scaling strategy.

Adding a powerful R&D dimension to the visit, Dr. Pisimisis also met with EditForce (editforce.co.jp), a pioneer in genome editing technologies. The collaboration discussions with EditForce brought forward exciting possibilities for integrating advanced genetic and molecular techniques into VITALE's development roadmap. Such integration is expected to significantly enhance VITALE's functionality, extend its application scope across life-science fields, and create opportunities for joint research initiatives, co-authored scientific publications, and grant applications in cutting-edge areas of biotechnology.

Moreover, the engagement with the EU–Japan Center for Industrial Cooperation (eu-japan.eu) provided a strategic foundation for facilitating broader technology transfer and regulatory alignment between the European and Japanese markets. This partnership will play a critical role in supporting AMGEL’s and VITALE's future commercialization by unlocking access to bilateral industrial networks, innovation ecosystems, and collaborative funding mechanisms.

Through these targeted interactions, EFEVRE TECH continues to strengthen its global innovation footprint, ensuring that the proposed VITALE software is built not only with technical excellence but also with the collaborative strength needed to thrive in international markets.

International Recognition and Market-Driven Feedback

Presenting VITALE at the 1st Business Cyprus–Japan Forum in 2024, marked the first introduction of the platform to a Japanese scientific audience. The reception was both enthusiastic and constructive, with several key takeaways:

The attended Japanese Life-Science researchers valued VITALE’s potential as a powerful tool, particularly for multicenter clinical studies and international trials.
Feedback highlighted the importance of multilingual interface support, especially in contexts where regulatory documentation and lab SOPs must comply with local languages.
Stakeholders from med-tech companies expressed interest in customizing the Protocol Designer for niche research areas, reinforcing the demand for modular design.
Importantly, investors and research leaders praised VITALE’s role in improving traceability, citing its relevance for data integrity and compliance under Japan’s Pharmaceutical and Medical Device Act (PMDA).

This dialogue provided the EFEVRE TECH team with valuable insights, not only to refine user interface and regulatory compatibility, but also to build new collaborations for pilot programs, clinical trials, and R&D partnerships in Asia.

“VITALE represents a new era of reproducibility—not through oversight, but through intelligent automation, researcher empowerment, and transparent data science”, said Dr. Pisimisis during the session.

Valuable Feedback from Reproductive Medicine Experts

Throughout the scientific conference, the EFEVRE TECH team engaged with researchers and practitioners to collect hands-on feedback on the needs and challenges faced by labs in reproductive medicine. This feedback directly informed several improvements in VITALE’s roadmap:

Enhanced protocol analyzation features within the protocol library page were requested to ensure full transparency across long-term and multi-step protocols, especially crucial in embryo handling and fertility research.
Role-based access controls were suggested to support laboratory teams with different permission levels, such as researchers, laboratory technicians, principal investigators, etc., in order to maintain compliance.

“VITALE is designed to empower scientists by enhancing and uplifting their daily work and ability to produce reliable, repeatable, and impactful results”, Dr. Kyriakou shared during one of his discussions with a scientific researcher.

Looking Ahead: Building Scientific Trust, One Connection at a Time

The 4th Panhellenic Conference of Reproductive Medicine offered more than just visibility for EFEVRE TECH, it offered validation, direction, and scientific legitimacy for the proposed VITALE project. The connections made, particularly with Professor Koutsilieris, are already helping the team reach deeper into the academic and clinical research community in the Greek market, positioning the VITALE software as a serious contender in the digital transformation of biomedical laboratories. As VITALE continues its development, the feedback received and momentum gained from this conference will help ensure that its next iterations are even more aligned with the real-world needs of scientists tackling some of the most delicate and complex challenges in modern medicine.

Stay tuned as we continue building VITALE—an intelligent foundation for the future of research!

The Project with the proposal number ENTERPRISES/0223/Sub-Call1/105 and project acronym VITALE is funded by the European Union Recovery and Resilience Facility of the NextGenerationEU instrument, through the Ίδρυμα Έρευνας και Καινοτομίας/Research and Innovation Foundation.